Nevro - NVRO Stock Forecast, Price & News

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Nevro in the last twelve months. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" NVRO shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in NVRO, but not buy additional shares or sell existing shares.
View NVRO analyst ratings or view top-rated stocks.

11 brokers have issued twelve-month price objectives for Nevro's stock. Their NVRO share price forecasts range from $31.00 to $95.00. On average, they expect the company's stock price to reach $50.30 in the next twelve months. This suggests a possible upside of 55.0% from the stock's current price.
View analysts price targets for NVRO or view top-rated stocks among Wall Street analysts.

Nevro's stock was trading at $39.60 at the beginning of 2023. Since then, NVRO stock has decreased by 18.0% and is now trading at $32.46.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 3rd 2023.
View our NVRO earnings forecast.

Nevro Corp. (NYSE:NVRO) posted its quarterly earnings results on Thursday, February, 16th. The medical equipment provider reported ($0.54) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.49) by $0.05. The medical equipment provider had revenue of $113.84 million for the quarter, compared to the consensus estimate of $113.70 million. Nevro had a net margin of 0.74% and a negative trailing twelve-month return on equity of 36.24%. The business's revenue for the quarter was up 10.8% compared to the same quarter last year. During the same quarter last year, the company earned ($0.86) EPS.

ETFs with the largest weight of Nevro (NYSE:NVRO) stock in their portfolio include iShares Neuroscience and Healthcare ETF (IBRN), SPDR S&P Health Care Equipment ETF (XHE), Fidelity Digital Health ETF (FDHT), ROBO Global Healthcare Technology and Innovation ETF (HTEC), BlackRock Future Health ETF (BMED), Principal Healthcare Innovators ETF (BTEC), First Trust BuyWrite Income ETF (FTHI).iShares U.S. Medical Devices ETF (IHI).

Nevro issued an update on its FY 2023 earnings guidance on Tuesday, February, 28th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $445.00 million-$455.00 million, compared to the consensus revenue estimate of $449.24 million.

9 employees have rated Nevro Chief Executive Officer D. Keith Grossman on Glassdoor.com. D. Keith Grossman has an approval rating of 68% among the company's employees.

Based on aggregate information from My MarketBeat watchlists, some companies that other Nevro investors own include AT&T (T), NVIDIA (NVDA), AbbVie (ABBV), Walt Disney (DIS), General Electric (GE), Micron Technology (MU), Gilead Sciences (GILD), Advanced Micro Devices (AMD), Adobe (ADBE) and Intuitive Surgical (ISRG).

Nevro trades on the New York Stock Exchange (NYSE) under the ticker symbol "NVRO."

Nevro's stock is owned by a number of institutional and retail investors. Top institutional investors include Norges Bank (3.58%), ArrowMark Colorado Holdings LLC (3.53%), Fred Alger Management LLC (3.34%), Millennium Management LLC (2.60%), Principal Financial Group Inc. (2.16%) and Geode Capital Management LLC (1.77%). Insiders that own company stock include D Keith Grossman, Elizabeth H Weatherman, Kashif Rashid, Kevin C Oboyle, Leslie Stretch, Michael F Demane, Michael F Demane, Niamh Louise Pellegrini and Shawn Mccormick.
View institutional ownership trends.

Shares of NVRO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of NVRO stock can currently be purchased for approximately $32.46.

Nevro (NYSE:NVRO) has a market capitalization of $1.15 billion and generates $406.36 million in revenue each year. The medical equipment provider earns $3 million in net income (profit) each year or ($0.01) on an earnings per share basis.

The company employs 1,087 workers across the globe.

Nevro's mailing address is 1800 BRIDGE PARKWAY, REDWOOD CITY CA, 94065. The official website for the company is www.nevro.com. The medical equipment provider can be reached via phone at (650) 251-0005 or via email at ir@nevro.com.